Information for Healthcare Professionals The only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer Apifiny™ Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment Copyright © 2008-2015, Armune BioScience, Inc. The only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer What is Apifiny? • Apifiny is a cancer specific blood test that measures the body’s immune system response to prostate cancer. • Apifiny measures eight autoantibodies released by the immune system in response to the presence of prostate cancer.1 • Apifiny autoantibodies were discovered by research conducted at the University of Michigan under the direction of Arul Chinnaiyan, MD, PhD.2 • Apifiny does NOT rely on PSA or a calculation based on various forms of PSA. When should I order Apifiny? • Apifiny may be used in men who have an elevated PSA (>2.5 ng/ml) and are considering a prostate biopsy. Why should I order Apifiny? • Apifiny measures cancer specific biological markers that may provide you with additional insight to support a clinical decision. • In most cases, you already have the patient’s age, PSA level, DRE result, personal and family health history. • Order Apifiny when additional, unique biological information may help to make a more informed clinical decision. Given the complexity of cancer risk assessment, obtaining additional biological information may provide insight to better inform an important clinical decision such as an initial or repeat biopsy. 1. Translational Oncology, 2015; 8, 106-111 2. New England Journal of Medicine 2015; 353:1224-1235 Apifiny™ Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment How do I interpret an Apifiny Score? Apifiny, combined with existing patient information and your clinical experience, may aid in the assessment of prostate cancer risk. Interpretation of Results for Lower Risk Patients: “In the most recent peer-reviewed published study on Apifiny,1 approximately 9 out of 10 men like you, with a score of less than 59, were cancer free.” Interpretation of Results for Higher Risk Patients: “In the most recent peer-reviewed published study on Apifiny,1 approximately 1 out 3 men like you, with a score of 59 or above, had prostate cancer. You may be at higher risk.” What will Apifiny cost my patients? Medicare, Medicaid, and private insurance companies may cover the cost of the Apifiny test. Current reimbursement and other payment information can be found on the company’s website at www.armune.com. Order Apifiny™ Test Kits today! Apifiny™ Prostate Cancer 0 Lower Risk 59 Higher Risk 100 Risk Assessment The only cancer specific, non-PSA blood test that may aid clinicians in the detection of prostate cancer Armune BioScience, Inc. 401 West Morgan Road Ann Arbor, MI 48108 Toll Free Helpline: 844-427-6863 www.armune.com Apifiny is performed in the Armune BioScience high-complexity CLIA laboratory. CT-029 Rev.03 06/08/15